Fluticasone Furoate/ Vilanterol 200/25 mcg

Phase 3

GSK plc (GSK)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in Asthma

AZNSymbicort pMDI + budesonide HFA pMDI

Drug Information

Target Indication

Asthma

Clinical Trial

NCT01686633

Last updated: 2/12/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA10/6/2008

Alisade

Adults, adolescents (12 years and over) and children (6 - 11 years). Alisade is indicated for the treatment of the symptoms of allergic rhinitis.

View on EMA

EMA1/11/2008

Avamys

Adults, adolescents (12 years and over) and children (6-11 years). Avamys is indicated for the treatment of the symptoms of allergic rhinitis.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

GSK

GSK plc

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

Daprodustat smallPhase 3

Anaemia

Amoxicillin-Potassium Clavulanate CombinationPhase 3

Sinusitis, Acute

diphtheria, tetanus, pertussis & Hib vaccinePhase 3

Tetanus

Rosiglitazone (BRL49653C)Phase 3

Diabetes Mellitus, Type 2

GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)Phase 3

Herpes Zoster

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts